Multicenter Trial For Patients With Acute Crohn's Disease

Teva Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Crohn's Disease

Treatments: Drug: etiprednol dicloacetate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00035503

IXR-201-19-166

Details and patient eligibility

About

The purpose of this study is to see if etiprednol dicloacetate is safe and effective for the treatment of acute Crohn's disease.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Must have active confirmed Crohn's disease with CDAI > 220 and < 400.
• Otherwise healthy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind